866-997-4948(US-Canada Toll Free)

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline Review, H1 2017

Published By :

Global Markets Direct

Published Date : Mar 2017

Category :

Pharmaceutical

No. of Pages : 261 Pages

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ebolavirus Infections (Ebola Hemorrhagic Fever) Pipeline Review, H1 2017, provides an overview of the Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease) pipeline landscape.

Ebola is a rare but deadly viral infection that causes bleeding inside and outside the body. Signs and symptoms include fever, severe headache, joint and muscle aches, sore throat, nausea and vomiting, diarrhea, chest pain and cough. Supportive therapy includes oxygen therapy, blood transfusions, intravenous fluids and pain relievers.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ebolavirus Infections (Ebola Hemorrhagic Fever) Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Ebolavirus Infections (Ebola Hemorrhagic Fever) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 5, 9, 43 and 26 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 14 and 6 molecules, respectively.

Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
Introduction 5
Ebolavirus Infections (Ebola Hemorrhagic Fever) Overview 6
Ebolavirus Infections (Ebola Hemorrhagic Fever) Therapeutics Development 7
Ebolavirus Infections (Ebola Hemorrhagic Fever) Therapeutics Assessment 21
Ebolavirus Infections (Ebola Hemorrhagic Fever) Companies Involved in Therapeutics Development 29
Ebolavirus Infections (Ebola Hemorrhagic Fever) Drug Profiles 54
Ebolavirus Infections (Ebola Hemorrhagic Fever) Dormant Projects 228
Ebolavirus Infections (Ebola Hemorrhagic Fever) Discontinued Products 231
Ebolavirus Infections (Ebola Hemorrhagic Fever) Product Development Milestones 232
Appendix 248

List of Tables
Number of Products under Development for Ebolavirus Infections (Ebola Hemorrhagic Fever), H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Products under Development by Companies, H1 2017 (Contd..4), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Ebolavirus Infections (Ebola Hemorrhagic Fever) Pipeline by Abivax SA, H1 2017
Ebolavirus Infections (Ebola Hemorrhagic Fever) Pipeline by AnGes MG Inc, H1 2017
Ebolavirus Infections (Ebola Hemorrhagic Fever) Pipeline by ANP Technologies Inc, H1 2017
Ebolavirus Infections (Ebola Hemorrhagic Fever) Pipeline by Arno Therapeutics Inc, H1 2017
Ebolavirus Infections (Ebola Hemorrhagic Fever) Pipeline by Atreca Inc, H1 2017
Ebolavirus Infections (Ebola Hemorrhagic Fever) Pipeline by BioCryst Pharmaceuticals Inc, H1 2017
Ebolavirus Infections (Ebola Hemorrhagic Fever) Pipeline by BioFactura Inc, H1 2017
Ebolavirus Infections (Ebola Hemorrhagic Fever) Pipeline by Celgene Corp, H1 2017
Ebolavirus Infections (Ebola Hemorrhagic Fever) Pipeline by Cocrystal Pharma Inc, H1 2017
Ebolavirus Infections (Ebola Hemorrhagic Fever) Pipeline by Emergent BioSolutions Inc, H1 2017
Ebolavirus Infections (Ebola Hemorrhagic Fever) Pipeline by Enyo Pharma SAS, H1 2017
Ebolavirus Infections (Ebola Hemorrhagic Fever) Pipeline by Etubics Corp, H1 2017
Ebolavirus Infections (Ebola Hemorrhagic Fever) Pipeline by Fab'entech SA, H1 2017
Ebolavirus Infections (Ebola Hemorrhagic Fever) Pipeline by GeoVax Labs Inc, H1 2017
Ebolavirus Infections (Ebola Hemorrhagic Fever) Pipeline by Gilead Sciences Inc, H1 2017
Ebolavirus Infections (Ebola Hemorrhagic Fever) Pipeline by GlaxoSmithKline Plc, H1 2017
Ebolavirus Infections (Ebola Hemorrhagic Fever) Pipeline by Globavir Biosciences Inc, H1 2017
Ebolavirus Infections (Ebola Hemorrhagic Fever) Pipeline by Hemispherx Biopharma Inc, H1 2017
Ebolavirus Infections (Ebola Hemorrhagic Fever) Pipeline by Humabs BioMed SA, H1 2017
Ebolavirus Infections (Ebola Hemorrhagic Fever) Pipeline by Immune Response BioPharma Inc, H1 2017
Ebolavirus Infections (Ebola Hemorrhagic Fever) Pipeline by Immunovaccine Inc, H1 2017
Ebolavirus Infections (Ebola Hemorrhagic Fever) Pipeline by Inovio Pharmaceuticals Inc, H1 2017
Ebolavirus Infections (Ebola Hemorrhagic Fever) Pipeline by Integrated BioTherapeutics Inc, H1 2017
Ebolavirus Infections (Ebola Hemorrhagic Fever) Pipeline by Johnson & Johnson, H1 2017
Ebolavirus Infections (Ebola Hemorrhagic Fever) Pipeline by Kineta Inc, H1 2017
Ebolavirus Infections (Ebola Hemorrhagic Fever) Pipeline by Medicago Inc, H1 2017
Ebolavirus Infections (Ebola Hemorrhagic Fever) Pipeline by Merck & Co Inc, H1 2017
Ebolavirus Infections (Ebola Hemorrhagic Fever) Pipeline by Microbiotix Inc, H1 2017
Ebolavirus Infections (Ebola Hemorrhagic Fever) Pipeline by Micropharm Ltd, H1 2017
Ebolavirus Infections (Ebola Hemorrhagic Fever) Pipeline by NanoViricides Inc, H1 2017
Ebolavirus Infections (Ebola Hemorrhagic Fever) Pipeline by Navigen Pharmaceuticals Inc, H1 2017
Ebolavirus Infections (Ebola Hemorrhagic Fever) Pipeline by Novavax Inc, H1 2017
Ebolavirus Infections (Ebola Hemorrhagic Fever) Pipeline by Peregrine Pharmaceuticals Inc, H1 2017
Ebolavirus Infections (Ebola Hemorrhagic Fever) Pipeline by Phelix Therapeutics LLC, H1 2017
Ebolavirus Infections (Ebola Hemorrhagic Fever) Pipeline by PlantForm Corp, H1 2017
Ebolavirus Infections (Ebola Hemorrhagic Fever) Pipeline by Profectus BioSciences Inc, H1 2017
Ebolavirus Infections (Ebola Hemorrhagic Fever) Pipeline by RedHill Biopharma Ltd, H1 2017
Ebolavirus Infections (Ebola Hemorrhagic Fever) Pipeline by Regeneron Pharmaceuticals Inc, H1 2017
Ebolavirus Infections (Ebola Hemorrhagic Fever) Pipeline by Rodos BioTarget GmbH, H1 2017
Ebolavirus Infections (Ebola Hemorrhagic Fever) Pipeline by SignPath Pharma Inc, H1 2017
Ebolavirus Infections (Ebola Hemorrhagic Fever) Pipeline by Sirnaomics Inc, H1 2017
Ebolavirus Infections (Ebola Hemorrhagic Fever) Pipeline by Soligenix Inc, H1 2017
Ebolavirus Infections (Ebola Hemorrhagic Fever) Pipeline by Taiga Biotechnologies Inc, H1 2017
Ebolavirus Infections (Ebola Hemorrhagic Fever) Pipeline by Tamir Biotechnology Inc, H1 2017
Ebolavirus Infections (Ebola Hemorrhagic Fever) Pipeline by TGV-Inhalonix Inc, H1 2017
Ebolavirus Infections (Ebola Hemorrhagic Fever) Pipeline by Toyama Chemical Co Ltd, H1 2017
Ebolavirus Infections (Ebola Hemorrhagic Fever) Pipeline by Vaccibody AS, H1 2017
Ebolavirus Infections (Ebola Hemorrhagic Fever) Pipeline by Vaxart Inc, H1 2017
Ebolavirus Infections (Ebola Hemorrhagic Fever) Pipeline by XBiotech Inc, H1 2017
Ebolavirus Infections (Ebola Hemorrhagic Fever) Pipeline by Zydus Cadila Healthcare Ltd, H1 2017
Ebolavirus Infections (Ebola Hemorrhagic Fever) Dormant Projects, H1 2017
Ebolavirus Infections (Ebola Hemorrhagic Fever) Dormant Projects, H1 2017 (Contd..1), H1 2017
Ebolavirus Infections (Ebola Hemorrhagic Fever) Dormant Projects, H1 2017 (Contd..2), H1 2017
Ebolavirus Infections (Ebola Hemorrhagic Fever) Discontinued Products, H1 2017

List of Figures
Number of Products under Development for Ebolavirus Infections (Ebola Hemorrhagic Fever), H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Top 10 Molecule Types, H1 2017
Number of Products by Stage and Top 10 Molecule Types, H1 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *